Navigation Links
Targanta in Medical Technology

Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria

... CHICAGO, Sept. 19 /PRNewswire/ -- targanta Therapeutics Corporation today released detailed d...s (cSSSI) in which the primary endpoints were met. targanta believes oritavancin's properties may give it dist...ize oritavancin for the treatment of cSSSI. About targanta Therapeutics ...

Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models

...overy Platform CHICAGO, Sept. 19 /PRNewswire/ -- targanta Therapeutics Corporation today released detailed d...tration (FDA) as a significant unmet medical need. targanta has developed a novel drug discovery platform thro...nt as a possible therapy for osteomyelitis. About targanta Therapeutics ...

Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria

... Vitro Methods CHICAGO, Sept. 19 /PRNewswire/ -- targanta Therapeutics Corporation today released data from ...lls (5- to 13-fold lower MICs against the spores); targanta believes that such a phenomenon has not been repor...s (cSSSI) in which the primary endpoints were met. targanta believes oritavancin's properties may give it dist...

Targanta Initiates Phase 2 Oritavancin Infrequent Dosing Study

...cSSSI CAMBRIDGE, Mass., Sept. 13 /PRNewswire/ -- targanta Therapeutics Corporation today announced the initi...amine safety data in all intent-to-treat patients. targanta expects to enroll a total of 300 patients in this ...n (cSSSI) in which the primary endpoints were met. targanta believes oritavancin's properties may give it dist...

Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics

...said Thomas Parr, Ph.D., Chief Scientific Officer, targanta Therapeutics. "These data further support oritavan...al treatment for serious bacterial infections, and targanta will continue to explore this potential through on...med by former developers Lilly and InterMune, Inc. targanta expects to file a New Drug Application (NDA) for o...

Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax

...val rate at 30 days. Researchers at USAMRIID and targanta concluded that their results provide impetus for i...velopers Eli Lilly and Company and InterMune, Inc. targanta expects to file a New Drug Application (NDA) for o...ministration in the first quarter of 2008. About targanta Therapeutics Corporation ...
Targanta in Biological Technology

InterMune Reports First Quarter 2009 Financial Results and Business Highlights

...ly $6.0 million received in the first quarter of 2009 from the acquisition by The Medicines Company of InterMune's approximately 3.0 million shares of targanta Therapeutics Corporation. On January 1, 2009, the company adopted Financial Accounting Standards Board Staff Position APB 14-1, "Accounting fo...

InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights

... completed its tender offer for all of the outstanding shares of targanta Therapeutics Corporation. Based on InterMune's ownership of approximately 3 million targanta shares, InterMune expects to receive approximately $6.0 million in t...

Targanta Submits Oritavancin New Drug Application

...lizations, and increased healthcare costs. About targanta Therapeutics targanta Therapeutics Corporation is a biopharmaceutical co...d Montreal, Quebec, Canada. To find out more about targanta Therapeutics Corp. (Nasdaq: TARG ), visit our web...

InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance

...lion, compared with $214.5 million at December 31, 2006. In October 2007, targanta Therapeutics completed an initial public offering of its common stock, which resulted in the conversion of InterMune's interest in targanta into approximately 3.0 million shares of Targanta common stock. As of Decem...

Targanta to Present at Lazard Capital Markets Fourth Annual Healthcare Conference

...ite at http://www.targanta.com/investors . About targanta Therapeutics targanta Therapeutics Corporation is a biopharmaceutical co...i-synthetic lipoglycopeptide antibiotic, for which targanta intends to seek U.S. regulatory approval in early ...

Targanta to Present at 9th Annual Mass Opportunities Investment Conference

...ite at http://www.targanta.com/investors . About targanta Therapeutics targanta Therapeutics Corporation is a biopharmaceutical co...i-synthetic lipoglycopeptide antibiotic, for which targanta intends to seek U.S. regulatory approval in early ...

Biotech Continues Upward Climb in October

... offering at $12, 20% below the midpoint of their proposed $14 to $16 range. During the month its shares strengthened to close at $13.88. -- targanta Therapeutics, which developing an antibiotic treatment for gram-positive bacterial infections, priced 5.8 million shares at $10 per share, 30%...

2007 Massachusetts Biotechnology Council MASS Opportunities Investment Conference Showcases Leading Growth Companies

...ticals, Molecular, Biometrics, Molecular Insight Pharmaceuticals, Momenta Pharmaceuticals, Nitromed Inc., Oscient Pharmaceuticals, Primera Biosystems, targanta Therapeutics, Transmolecular Inc, Transport Pharmaceuticals, Vertex Pharmaceuticals, and Ziopharm. Last year was a banner year for venture capital fi...

Targanta Therapeutics Announces Pricing of its Initial Public Offering

.... All of the shares are being offered by Targanta. targanta has granted to the underwriters a 30-day option to...ies laws of any such state or jurisdiction. About targanta Therapeutics targanta Therapeutics Corporation is a biopharmaceutical co...

Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting

...eting CAMBRIDGE, Mass., Sept. 12 /PRNewswire/ -- targanta Therapeutics Corporation today announced that 23 p.... Thomas Parr, Ph.D., Chief Scientific Officer of targanta Therapeutics commented on the meeting: "We are ver...d of the body of data being presented on behalf of targanta at ICAAC this year-a true testament, we believe, t...
Other Tags
(Date:4/23/2014)... mounts showing the potential health benefits of probiotics, antioxidants ... taking supplements. And the chemical industry is getting in ... effects could deter growth, so the industry is responding ... to the cover story in Chemical & Engineering ... American Chemical Society. , Melody M. Bomgardner, a senior ...
(Date:4/23/2014)... for-profit and non-profit organizations in Washington will receive ... Concept grants to accelerate maturation of promising health-related ... Sciences Discovery Fund (LSDF) announced today. Also announced ... the Washington Biotechnology & Biomedical Association (WBBA) to ... next generation of entrepreneurs and help early-stage companies ...
(Date:4/23/2014)... Physical Activity on Mobility Limitation in Old Age , ... of mobility limitation in old age, whereas leisure-time physical ... study which followed up 5,200 public sector employees for ... Research Center in Finland and the Finnish Institute of ... wears the body and lasts for several hours a ...
(Date:4/23/2014)... studies have shown that proliferation of endogenous neural ... to neurons and axons. From the perspective of ... Sun Yat-sen University in China observed the effects ... precursor cell proliferation and expression of basic fibroblast ... rat brain on the infarct side. The researchers ...
(Date:4/22/2014)... visited the New Jersey Institute of Technology (NJIT) ... for the launch of the New Jersey Innovation ... new model for business innovation through the leveraging ... investment. U.S. Senator Cory Booker, Panasonic Corp. of ... Jersey Lieutenant Governor Kim Guadagno, New Jersey Secretary ...
Breaking Medicine News(10 mins):Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2
(Date:4/22/2014)... lead a five-year, $3 million study to determine whether ... transport of dissolved organic matter (DOM) through the Connecticut ... chemical composition and water quality of the watershed and ... Science Foundation,s MacroSystems Biology program, researchers will collect data ... in Canada and runs through five U.S. states, before ...
(Date:4/22/2014)... JUPITER, FL, April 22, 2014 Scientists from the ... identified a protein complex that plays a critical but ... , The study, which showed a novel role for ... 2014 in the journal eLife , a publisher ... Planck Society and the Wellcome Trust. , "This is ...
(Date:4/22/2014)... Inspired by the fist-like club of a mantis ... California, Riverside, in collaboration with University of Southern California ... composite materials that is more impact resistant and tougher ... we study the club of this tiny crustacean, the ... things we use every day," said David Kisailus, a ...
Breaking Biology News(10 mins):Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3Scientists identify critical new protein complex involved in learning and memory 2Mantis shrimp stronger than airplanes 2Mantis shrimp stronger than airplanes 3
Other Contents